Simulations Plus

Simulations Plus, Inc. provides modeling and simulation software and consulting services supporting drug discovery, development research and regulatory submissions. The firm operates through the Software and Services segment. It designs and develops pharmaceutical simulation software to promote cost-effective solutions to a number of problems in pharmaceutical research and in the education of pharmacy and medical students. The company was founded by Walter S. Woltosz and Virginia E. Woltosz on July 17, 1996 and is headquartered in Lancaster, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Simulations Plus reports Q1 revenue decline, eyes global expansion

Simulations Plus (SLP) navigated Q1 challenges with a focus on innovation, growth, and shareholder value.
Balancing revenue streams and exploring global opportunities position the company for future success.
Commitment to science, R&D, and market expansion underscores strategic vision and adaptability.
Positive outlook for future quarters driven by achievements, market traction, and evolving strategies.

Simulations Plus reports solid Q2 earnings, eyes growth opportunities

Simulations Plus delivered a strong quarter with revenue and net income growth.
The company's focus on collaborations and AI technologies bodes well for future growth.
Challenges in certain software products and economic impacts on sales cycles noted.
Opportunities in agrochemicals, biosimilars, and inorganic growth avenues are being pursued.

Simulations Plus (SLP) reports strong Q3 earnings and expands into oncology with Immunetrics acquisition

Simulations Plus (SLP) delivered a robust performance in Q3 2023, driven by revenue growth, strategic acquisitions, and operational initiatives.
While facing challenges such as renewal rate fluctuations, SLP remains well-positioned to capitalize on opportunities for growth and expansion.
Guidance for fiscal 2023, strong backlog visibility, and the Immunetrics acquisition underscore SLP's positive trajectory and potential for sustained success.

Simulations Plus (SLP) posts strong Q4 results, eyes biosimulation growth

Simulations Plus (SLP) delivered a solid performance in Q4 2023, showcasing revenue growth, strong margins, and notable achievements. While facing challenges from market conditions and nonrenewals, the company is optimistic about growth opportunities in biosimulation and revenue contributions from the Immunetrics acquisition.

Simulations Plus (SLP) reports stellar Q1 results and eyes growth

Simulations Plus (SLP) demonstrated robust performance across key segments, with strong revenue growth and profitability metrics.
While facing challenges like varied client budgets and revenue declines in certain units, the company is well-positioned to capitalize on growth opportunities.
With a focus on customer loyalty, operational efficiency, and strategic investments, Simulations Plus is poised for continued success in the market.

Simulations Plus (SLP) reports strong Q2 growth and outlook

Simulations Plus (SLP) demonstrated robust growth in Q2 2024
Strong performance in both Software and Services segments
Positive market outlook and strategic positioning for future growth
Focused on meeting fiscal 2024 guidance targets

Simulations Plus Reports Strong Q3, Eyes Growth Initiatives

Simulations Plus delivered a strong performance in Q3 2024, driven by growth in both software and services. The launch of new software and the acquisition of Pro-ficiency highlight strategic moves to enhance offerings and market position. However, challenges in gross margin and client spending patterns could impact future performance. Overall, the company remains focused on growth and operational integration.

Simulations Plus beats earnings expectations, eyes TAM expansion opportunities

Simulations Plus delivered strong financial results, exceeding revenue and EPS expectations. While facing challenges in meeting organic growth targets, the company's strategic investments and acquisitions position it well for future growth. With a focus on expanding TAM and maintaining profitability, Simulations Plus remains optimistic about its prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today reported financial results for the 1st quarter of fiscal year 2024; details will be discussed in a conference call at 5pm ET.

Simulations Plus Reports First Quarter Fiscal 2024 Financial Results

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced several key leadership appointments and promotions today, including the addition of Dan Szot as Chief Revenue Officer.

Simulations Plus Announces Leadership Appointments Supporting Commitment to Clients and Driving Growth

Simulations Plus (SLP) fiscal first-quarter performance is likely to have benefited from momentum across Software and Services business segments.

Simulations Plus (SLP) to Report Q1 Earnings: What's in Store?

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report first quarter fiscal 2024 financial results after the market close on Wednesday, January 3, 2024. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and prospective shareholders are invited to join the live webcast by registering here. The conference call can also be accesse.

Simulations Plus Announces First Quarter Fiscal Year 2024 Earnings and Conference Call Date

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus will host a virtual investor day today, Nov. 14, 2023, starting at 1:00 pm ET, with presentations by the Company's leadership team.

Simulations Plus Outlines Paths to Win at 2023 Investor Day

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus CEO, Shawn O'Connor, and the leadership team will participate in the Company's virtual Investor Day on Tuesday, Nov 14, at 1 p.m. ET.

Simulations Plus to Host Investor Day on Tuesday, November 14th

Simulations Plus, Inc. (NASDAQ:SLP ) Q4 2023 Earnings Conference Call October 25, 2023 5:00 PM ET Company Participants Tamara Gonzales - Investor Relations, Financial Profiles Shawn O'Connor - Chief Executive Officer Will Frederick - Chief Financial Officer Conference Call Participants Francois Brisebois - Oppenheimer Matt Hewitt - Craig-Hallum David Larsen - BTIG David Windley - Jefferies Operator Greetings, and welcome to the Simulations Plus Fourth Quarter Fiscal 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Simulations Plus, Inc. (SLP) Q4 2023 Earnings Call Transcript

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today reported financial results for the 4th quarter and full fiscal year 2023. Total FY23 revenue increased 11% to $59.6 million.

Simulations Plus Reports Fourth Quarter and Fiscal 2023 Financial Results

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus will host a conference call & webcast on October 25, 2023, at 5pm ET to discuss 4th quarter & fiscal year 2023 financial results.

Simulations Plus Announces Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus was awarded a new funded grant from the U.S. FDA to validate best practices for PBBM/PBPK modeling workflows to simulate VBE studies.

Simulations Plus Receives New FDA Grant Award

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus hosted its first University+ PBPK Summer Camp, an intensive 8-week PBPK modeling course for more than 80 attendees from 26 countries.

Simulations Plus Hosts First-of-its-Kind Virtual Summer Camp for Students and Professors

LANCASTER, Calif.--(BUSINESS WIRE)--Dr. Viera Lukacova, Chief Science Officer of Simulations Plus, was selected to be a Fellow of the American Association of Pharmaceutical Scientists.

Simulations Plus Chief Science Officer Dr. Viera Lukacova Honored as Fellow by the American Association of Pharmaceutical Scientists (AAPS)

LANCASTER, Calif.--(BUSINESS WIRE)--The July 2023 issue of Clinical Pharmacology & Therapeutics published research where DILIsym was used to predict liver safety of CBD & VPA treatments.

Researchers Use the Simulations Plus DILIsym® Platform to Predict Safety of Combined CBD and VPA Treatment

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced the release of ADMET Predictor 11 with significant enhancements expressly designed to accelerate drug discovery research.

Simulations Plus Releases ADMET Predictor® 11

Simulations Plus' (SLP) third-quarter fiscal 2023 top line is driven by higher revenues in the Software and Services business segments.

Simulations Plus (SLP) Q3 Earnings Miss, Revenues Rise Y/Y

Simulations Plus, Inc. (NASDAQ:SLP ) Q3 2023 Earnings Conference Call July 6, 2023 5:00 PM ET Company Participants John Wilfong - Investor Relations, Financial Profiles Shawn O'Connor - Chief Executive Officer Will Frederick - Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum David Larsen - BTIG Yuan Zhi - B. Riley Francois Brisebois - Oppenheimer Operator Greetings, and welcome to the Simulations Plus Third Quarter Fiscal 2023 Financial Results Conference Call.

Simulations Plus, Inc. (SLP) Q3 2023 Earnings Call Transcript

Simulations Plus (SLP) came out with quarterly earnings of $0.20 per share, missing the Zacks Consensus Estimate of $0.21 per share. This compares to earnings of $0.20 per share a year ago.

Simulations Plus (SLP) Q3 Earnings Miss Estimates

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today reported revenue growth in the 3rd quarter of FY23 with 3Q revenue up 9% to $16.2 million; 9mo revenue up 4% to $43.9 million.

Simulations Plus Reports Third Quarter Fiscal 2023 Financial Results

Simulations Plus' (SLP) third-quarter performance is likely to have gained from the healthy adoption of its solutions across various verticals amid continued macroeconomic weakness.

Simulations Plus (SLP) to Report Q3 Earnings: What's in Store?

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus will host a conference call and webcast on July 6, 2023, at 5pm EDT to discuss the financial results from the 3rd quarter of FY2023.

Simulations Plus Announces Third Quarter Fiscal Year 2023 Earnings and Conference Call Date

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced today the acquisition of Immunetrics, Inc., an addition of important and proven QSP technology in new therapeutic areas.

Simulations Plus Acquires Immunetrics to Expand its Immunology and Oncology Drug Development Capabilities

Tencent Music Entertainment Group 

Ternium

Epsilon Energy Ltd

Gulf Resources

Inmode Ltd

NuScale Power Corp

While it's a general rule of thumb that you get what you pay for, in the market, you can sneak in some overlooked compelling discounts, which might be the case with the below best affordable stocks to invest in. With a price tag under $50, these enterprises facilitate approachability while also delivering on the quality or relevance components.

7 Stocks Under $50 to Buy (and Never Sell)

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced today the release of a targeted package of software and services for accelerating pulmonary drug discovery and development.

Simulations Plus Launches New Integrated Pulmonary Software and Services Package to Streamline Drug Development and Improve Patient Outcomes

Simulations Plus, Inc. is a company that develops software for drug discovery and development using artificial intelligence and machine learning technology. SLP has seen what was very impressive growth begin to quickly slow.

Simulations Plus: Overhyped With No Growth Left

Asure Software

Atlassian

Zscaler

Investors can consider adding four low-beta tech stocks like TEAM, ZS, SLP and ASUR in their portfolios to hedge against a highly-volatile market.

News for Simulations Plus Stock (SLP)